Article
Medicine, General & Internal
Marta Morawska, Jadwiga Dwilewicz-Trojaczek, Tomasz Stompor, Piotr Ligocki, Marek Stopinski, Michal Sutkowski, Norbert Grzasko, Anna Kordecka, Mariusz Kordecki, Artur Jurczyszyn, Dominik Dytfeld, Tomasz Wrobel, Krzysztof Jamroziak, Agnieszka Druzd-Sitek, Adam Walter-Croneck, Krzysztof Giannopoulos
Summary: This study developed a 3-step screening protocol for monoclonal gammopathies and multiple myeloma, which proved to be efficient in diagnosis. The protocol can help standardize the understanding of clinical manifestation and diagnostic methods among primary care physicians.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Immunology
Tong Li, Hongjie Liu, Wei Li
Summary: Cutaneous vesiculobullous eruptions are rare in multiple myeloma patients. This study reports a unique case of an MM patient with both flaccid and tense vesicles and bullae. Direct immunofluorescence revealed an atypical autoantibody deposition pattern. A literature review identified 17 previously reported cases of autoimmune bullous diseases associated with MM, with similar cutaneous involvement patterns.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Dickran Kazandjian, Elizabeth Hill, Alexander Dew, Candis Morrison, Joseph Roswarski, Neha Korde, Michael Emanuel, Ani Petrosyan, Manisha Bhutani, Katherine R. Calvo, Alina Dulau-Florea, Mary Kwok, Min-Jung Lee, Sunmin Lee, Liza Lindenberg, Sham Mailankody, Elisabet Manasanch, Irina Maric, Esther Mena, Nisha Patel, Nishant Tageja, Jane B. Trepel, Baris Turkbey, Hao-Wei Wang, Weixin Wang, Constance Yuan, Yong Zhang, Raul Braylan, Peter Choyke, Maryalice Stetler-Stevenson, Seth M. Steinberg, William D. Figg, Mark Roschewski, Ola Landgren
Summary: Treatment with novel triplet regimens such as KRd and lenalidomide maintenance therapy for high-risk smoldering myeloma may significantly delay the progression to symptomatic multiple myeloma, altering the natural history of the disease. Further randomized clinical trials are needed to confirm the favorable benefit-to-risk profile observed in this phase 2 trial.
Article
Urology & Nephrology
Lihong Bu, Vincent Javaugue, Sophie Chauvet, Jerold Napier, Surendra Dasari, Jason D. Theis, Julie A. Vrana, Ellen D. McPhail, Samih H. Nasr
Summary: This case report presents a patient with high-risk K light chain multiple myeloma who developed immunotactoid glomerulopathy and myeloma cast nephropathy. The glomerular microtubular deposits stained only for K light chain and C3. Proteomic analysis confirmed the presence of K light chain constant domain and a single VL variability subgroup in both glomeruli and casts. Despite clone-directed chemotherapy, the patient remained dependent on dialysis treatment. The pathogenesis of this light chain-only variant of immunotactoid glomerulopathy may involve activation of the alternative pathway of complement by a nephrotoxic K light chain.
AMERICAN JOURNAL OF KIDNEY DISEASES
(2023)
Review
Oncology
Manisha Bhutani, Brandon J. Blue, Craig Cole, Ashraf Z. Badros, Saad Z. Usmani, Ajay K. Nooka, Leon Bernal-Mizrachi, Joseph Mikhael
Summary: This review examines the disparities in incidence, diagnosis, treatment access, clinical trial participation, and healthcare utilization that negatively impact outcomes for African American patients with multiple myeloma. It emphasizes the role of healthcare providers in addressing these disparities by considering historical, sociocultural, individual, and disease-related factors. The review provides insights into both biological and non-biological disparities, barriers to clinical care, and best practices for ensuring that African American patients receive optimal care.
BLOOD CANCER JOURNAL
(2023)
Article
Hematology
Carolina Schinke, Alexandra M. Poos, Michael Bauer, Lukas John, Sarah Johnson, Shayu Deshpande, Luis Carrillo, Daisy Alapat, Leo Rasche, Sharmilan Thanendrarajan, Maurizio Zangari, Samer Al Hadidi, Frits van Rhee, Faith Davies, Marc S. Raab, Gareth Morgan, Niels Weinhold
Summary: This study used single-cell RNA sequencing to analyze bone marrow cells at different stages of multiple myeloma (MM) and found changes in immune cell populations during disease progression. These changes included a decrease in memory and naive CD4 T cells, an increase in CD8+ effector T cells and T-regulatory cells, as well as an enrichment of nonclonal memory B cells and CD14, CD16 monocytes. These findings provide important information for understanding the immune changes in MM and for patient stratification and early therapeutic intervention.
Article
Biochemistry & Molecular Biology
Federico Canzian, Chiara Piredda, Angelica Macauda, Daria Zawirska, Niels Frost Andersen, Arnon Nagler, Jan Maciej Zaucha, Grzegorz Mazur, Charles Dumontet, Marzena Watek, Krzysztof Jamroziak, Juan Sainz, Judit Varkonyi, Aleksandra Butrym, Katia Beider, Niels Abildgaard, Fabienne Lesueur, Marek Dudzinski, Annette Juul Vangsted, Matteo Pelosini, Edyta Subocz, Mario Petrini, Gabriele Buda, Malgorzata Razny, Federica Gemignani, Herlander Marques, Enrico Orciuolo, Katalin Kadar, Artur Jurczyszyn, Agnieszka Druzd-Sitek, Ulla Vogel, Vibeke Andersen, Rui Manuel Reis, Anna Suska, Herve Avet-Loiseau, Marcin Kruszewski, Waldemar Tomczak, Marcin Rymko, Stephane Minvielle, Daniele Campa
Summary: Multiple myeloma (MM) risk has a strong genetic background, with 23 risk loci identified through genome-wide association studies (GWAS). Combining SNPs into a polygenic risk score (PRS) showed significant associations with MM risk, providing a first step towards using genetics for risk stratification in the general population.
EUROPEAN JOURNAL OF HUMAN GENETICS
(2022)
Review
Medicine, General & Internal
Hua Huang, Shen-Xian Qian
Summary: Lichen myxedematosus (LM) combined with monoclonal gammopathy of undetermined significance (MGUS) can be diagnosed as scleromyxedema. However, we report a case of generalized papules combined with MGUS that was eventually diagnosed as atypical or intermediate forms of LM because it only involved the skin and the pathological type was not consistent with scleromyxedema. There have been few reports on atypical or intermediate forms of LM, making the course of the disease unpredictable.
FRONTIERS IN MEDICINE
(2023)
Article
Oncology
Laura Duran-Lozano, Gudmar Thorleifsson, Aitzkoa Lopez de Lapuente Portilla, Abhishek Niroula, Molly Went, Malte Thodberg, Maroulio Pertesi, Ram Ajore, Caterina Cafaro, Pall I. Olason, Lilja Stefansdottir, G. Bragi Walters, Gisli H. Halldorsson, Ingemar Turesson, Martin F. Kaiser, Niels Weinhold, Niels Abildgaard, Niels Frost Andersen, Ulf-Henrik Mellqvist, Anders Waage, Annette Juul-Vangsted, Unnur Thorsteinsdottir, Markus Hansson, Richard Houlston, Thorunn Rafnar, Kari Stefansson, Bjorn Nilsson
Summary: A new MM risk variant at SOHLH2 on chromosome 13q13.3 was identified in a genome-wide association study involving 5,320 cases and 422,289 controls from Nordic populations. This variant influences transcriptional activity in plasma cells and represents a novel insight into MM susceptibility.
BLOOD CANCER JOURNAL
(2021)
Article
Oncology
Rosalinda Termini, David Zihala, Evangelos Terpos, Albert Perez-Montana, Tomas Jelinek, Marc Raab, Niels Weinhold, Elias K. Mai, Anna Luise Grab, Jill Corre, Francois Vergez, Antonio Sacco, Marco Chiarini, Viviana Giustini, Alessandra Tucci, Sara Rodriguez, Cristina Moreno, Cristina Perez, Catarina Maia, Esperanza Martin-Sanchez, Camilla Guerrero, Cirino Botta, Juan-Jose Garces, Aitziber Lopez, Luis-Esteban Tamariz-Amador, Felipe Prosper, Joan Bargay, Maria-Elena Cabezudo, Enrique M. Ocio, Roman Hajek, Joaquin Martinez-Lopez, Fernando Solano, Rebeca Iglesias, Artur Paiva, Catarina Geraldes, Helena Vitoria, Clara Gomez, Felipe De Arriba, Heinz Ludwig, Antoni Garcia-Guinon, Maria Casanova, Adrian Alegre, Valentin Cabanas, Maialen Sirvent, Albert Oriol, Javier de la Rubia, Jose-Angel Hernandez-Rivas, Luis Palomera, Maria Sarasa, Pablo Rios, Noemi Puig, Maria-Victoria Mateos, Juan Flores-Montero, Alberto Orfao, Hartmut Goldschmidt, Herve Avet-Loiseau, Aldo M. Roccaro, Jesus F. San-Miguel, Bruno Paiva
Summary: This study suggests that measuring circulating tumor cells (CTCs) in peripheral blood is more accurate than bone marrow plasma cells (BM PCs) for assessing tumor burden in smoldering multiple myeloma (SMM). Combining the 20/2/0.015 model with an immune risk score based on specific immune cell percentages allows for better risk stratification of SMM patients.
CLINICAL CANCER RESEARCH
(2022)
Review
Hematology
Heinz Ludwig, Pieter Sonneveld, Thierry Facon, Jesus San-Miguel, Herve Avet-Loiseau, Mohamad Mohty, Maria-Victoria Mateos, Philippe Moreau, Michele Cavo, Charlotte Pawlyn, Sonja Zweegman, Monika Engelhardt, Christoph Driessen, Gordon Cook, Melitios A. Dimopoulos, Francesca Gay, Hermann Einsele, Michel Delforge, Jo Caers, Katja Weisel, Graham Jackson, Laurent Garderet, Niels van de Donk, Xavier Leleu, Hartmut Goldschmidt, Meral Beksac, Inger Nijhof, Martin Schreder, Niels Abildgaard, Roman Hajek, Niklas Zojer, Efstathios Kastritis, Annemiek Broijl, Fredrik Schjesvold, Mario Boccadoro, Evangelos Terpos
Summary: Patients with multiple myeloma are at increased risk of infection and mortality related to SARS-CoV-2 virus, and may have suboptimal immune response to vaccination, highlighting the importance of monitoring and adapting vaccination strategies for this vulnerable population.
LANCET HAEMATOLOGY
(2021)
Article
Oncology
Romanos Sklavenitis-Pistofidis, Michelle P. Aranha, Robert A. Redd, Joanna Baginska, Nicholas J. Haradhvala, Margaret Hallisey, Ankit K. Dutta, Alexandra Savell, Shohreh Varmeh, Daniel Heilpern-Mallory, Sylvia Ujwary, Oksana Zavidij, Francois Aguet, Nang K. Su, Elizabeth D. Lightbody, Mark Bustoros, Sabrin Tahnri, Tarek H. Mouhieddine, Ting Wu, Lea Flechon, Shankara Anand, Jacalyn M. Rosenblatt, Jeffrey Zonder, James J. Vredenburgh, Adam Boruchov, Manisha Bhutani, Saad Z. Usmani, Jeffrey Matous, Andrew J. Yee, Andrzej Jakubowiak, Jacob Laubach, Salomon Manier, Omar Nadeem, Paul Richardson, Ashraf Z. Badros, Maria-Victoria Mateos, Lorenzo Trippa, Gad Getz, Irene M. Ghobrial
Summary: This study found that early treatment with EloLenDex is safe and effective for high-risk SMM patients, and provides a comprehensive characterization of alterations in immune cell composition and TCR repertoire diversity in patients. The study also revealed that the similarity of a patient's immune cell composition to that of healthy donors may have prognostic relevance at diagnosis and after treatment.
Article
Hematology
Junjie Huang, Sze Chai Chan, Veeleah Lok, Lin Zhang, Don Eliseo Lucero-Prisno, Wanghong Xu, Zhi-Jie Zheng, Edmar Elcarte, Mellissa Withers, Martin C. S. Wong
Summary: The global incidence and mortality of multiple myeloma in 2020 showed an increasing trend, with higher rates observed in countries such as Australia, New Zealand, northern America, and northern Europe. Lower rates were observed in western Africa, Melanesia, and southeastern Asia. The incidence increase was more pronounced in men, individuals aged 50 years or older, and high-income countries. However, there was an overall decreasing trend in multiple myeloma mortality, with women showing a more significant decrease. Improving lifestyle habits, diagnosis capacity, and treatment availability is crucial in controlling the rising trends of multiple myeloma in high-risk populations.
LANCET HAEMATOLOGY
(2022)
Article
Multidisciplinary Sciences
John H. Huber, Mengmeng Ji, Yi-Hsuan Shih, Mei Wang, Graham Colditz, Su-Hsin Chang
Summary: In this study, a mathematical model was used to analyze nationally representative data from the United States and found that the difference in multiple myeloma incidence can be explained by an increased incidence of monoclonal gammopathy of undetermined significance (MGUS) among male and non-Hispanic Black populations. There was no evidence showing differences in the rate of progression from MGUS to multiple myeloma by either gender or race/ethnicity. The results suggest that screening for MGUS among high-risk groups, such as non-Hispanic Black men, may be a promising strategy to reduce the burden and disparities in multiple myeloma health.
NATURE COMMUNICATIONS
(2023)
Article
Medicine, General & Internal
Maria A. Kelley, Andrea Mestre, Maria F. Ayau, Arpit Arora, Ratesh Khillan
Summary: Non-secretory multiple myeloma (NSMM) is a rare hematological malignancy characterized by the inability of plasmacytic cells to secrete or synthesize immunoglobulins. This article presents a case report illustrating the differences in pathophysiology, clinical features, diagnosis, and management compared to secretory multiple myeloma.
CUREUS JOURNAL OF MEDICAL SCIENCE
(2022)